IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Menlo Therapeutics Inc

CUSIP: 586858902 | 3 institutional holders

Quarters

Q2 2020Q1 2020
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile